Related Experiment Video
Updated: May 6, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Targeting ALK in patients with advanced non small cell lung cancer: biology, diagnostic and therapeutic options
Chiara Lazzari1, Gianluca Spitaleri1, Chiara Catania1
1European Institute of Oncology, Division of Thoracic Oncology, Italy.
Abstract:
The discovery of EML4-ALK fusion gene in a subgroup of patients with lung adenocarcinoma led to the development of a new class of agents, the ALK inhibitors, and dramatically improved the clinical outcome of these patients. The striking results from clinical trials with crizotinib, the first ALK inhibitor evaluated, allowed the accelerated approval of crizotinib from the USA Food and Drug Administration (FDA). Despite the high initial results, patients acquire resistance to crizotinib, and different next generation ALK kinase inhibitors have been developed. In the current review, we will analyze the biology of EML4-ALK gene, the acquired resistance mechanisms to crizotinib, the therapeutic strategies, currently under evaluation, designed to overcome crizotinib resistance, and the open issues that need to be addressed in order to improve outcome in ALK+ Non Small Cell Lung Cancer (NSCLC) patients.
Insights
The EML4-ALK fusion gene discovery revolutionized lung cancer treatment with ALK inhibitors. Despite initial success, resistance emerges, necessitating new strategies for ALK-positive Non-Small Cell Lung Cancer (NSCLC) patients.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The EML4-ALK fusion gene is a key driver in a subset of lung adenocarcinoma.
- ALK inhibitors, like crizotinib, have transformed treatment for ALK-positive Non-Small Cell Lung Cancer (NSCLC).
- Crizotinib received accelerated FDA approval due to significant clinical benefits.
Purpose of the Study:
- To review the biology of the EML4-ALK fusion gene.
- To analyze mechanisms of acquired resistance to crizotinib.
- To discuss therapeutic strategies for overcoming resistance and improve outcomes in ALK+ NSCLC.
Main Methods:
- Literature review of EML4-ALK biology.
- Analysis of resistance mechanisms to ALK inhibitors.
- Evaluation of emerging therapeutic strategies.
Main Results:
- EML4-ALK fusion drives oncogenesis in a specific lung cancer group.
- Acquired resistance to crizotinib is a significant clinical challenge.
- Next-generation ALK inhibitors are being developed to address resistance.
Conclusions:
- Understanding EML4-ALK biology is crucial for targeted therapy.
- Overcoming crizotinib resistance is essential for long-term patient survival.
- Further research is needed to optimize treatment for ALK+ NSCLC.
More Related Videos
05:17Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
Published on: October 10, 2025
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies